http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Preventive pharmacotherapy of headache disorders
Methodology of prophylactic trials -- Principles of preventive pharmacotherapy in primary headache -- Methodology and implementation of systematic reviews -- Adverse events, equally important as efficacy as an outcome parameter? -- The methodology of prophylactic trials : discussion summary -- Prophylactic drugs I -- Key issues in the methodology of prophylactic migraine trials -- Migraine prophylaxis : a pharmacoepidemiological study of practices used by general practitioners and neurologists in France -- Preventive treatment of migraine headache with rofecoxib -- Prophylactic treatment and course of the disease in headache associated with sexual activity -- Prophylactic drugs I : discussion summary -- Prophylactic drugs II -- Prevention of migraine : beta-blockers and amine agonists : efficacy -- AEDs in migraine prevention -- Mechanism(s) of action of the antiepileptic drugs valproic acid, gabapentin, and topiramate : implications for the prophylactic management of migraine -- Experience with topiramate in patients with refractory migraine -- Topiramate in a selective group of therapy refractory headache patients -- Prophylactic drugs II : discussion summary -- Prophylactic drugs III -- Efficacy of antidepressants in heachache prophylaxis -- Antidepressants : mechanisms of action -- Other prophylactic anti-migraine agents : riboflavin, feverfew, magnesium, botulinum toxin, and calcium antagonists -- Treatment of chronic tension-type headache with mirtazapine -- Botulinum toxin type A in the treatment of refractory headache -- Botulinum toxin A in the prophylaxis of migraine - a double-blind , placebo-controlled, randomized study comparing frontal and cervical injection
Mechanisms of the antinociceptive effect of subcutaneous BOTOX® : inhibition of peripheral and central nociceptive processing -- Survey of expenditure for analgesics in chronic tension headache and its changes following botulinum toxin type A preventive treatment -- Prophylactic treatment of migraine with lomerizine hydrochloride -- Prophylactic drugs III : discussion summary -- Antagonizing peripheral sensitization in migraine -- New possibilities for antimigraine therapy via 5-HT receptors? -- Dihydroergotamine interaction with 5-HT₂ receptors and its relevance to migraine -- Migraine prophlaxis with drugs influencing the angiotension system -- Naratriptan in the preventive treatment of refractory chronic migraine -- PROMISE study (PROphylaxis of MIgraine with SEglor®) -- Serotonin receptors and migraine prophylaxis - the case of dihydroergotamine -- What is the mechanism of action of ACE inhibitors in migraine prophylaxis? -- Triptans with methysergide -- New targets I : discussion summary -- Nitric oxide and its signalling pathways : a rich source of potential targets for migrain therapy -- Clacitonin gene-related peptide and migriane -- Phosphodiesterases, cyclic nucleotides, and their role in the migraine -- The prostoglandin-E₁-analog misoprostol in the prophylactic treatment of refractory cluster headache and trigeminal neuralgia -- New tagets II : discussion summary
edited by Jes Olesen, Stephen D. Silberstein and Peter [as printed] Tfelt-Hansen.
Includes bibliographical references and index.